Kolexia
Rios Maria Oncologie médicale
Rios Maria
Oncologie médicale
Institut de cancérologie de Lorraine
Vandoeuvre-lès-Nancy, France
123 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Sarcomes Tumeurs du sein Tumeurs stromales gastro-intestinales Récidive tumorale locale Léiomyosarcome Métastase tumorale Tumeurs des tissus mous Seconde tumeur primitive Chondrosarcome

Collaborateurs

Voir plus
Blay Jean Yves
Blay Jean Yves
Centre Léon-Bérard, Lyon, France
Duffaud Florence
Duffaud Florence
Hôpital La Timone, Marseille, France
Bertucci Francois
Bertucci Francois
Centre Paoli-Calmettes, Marseille, France
Bompas Emmanuelle
Bompas Emmanuelle
Institut de cancérologie de l'Ouest, Saint-Herblain, France

Industries

Voir plus
Novartis
2 collaboration(s)
Dernière en 2020
Parexel
1 collaboration(s)
Dernière en 2021
Pfizer
1 collaboration(s)
Dernière en 2021
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
CHIC-STS01: Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma
Essai Clinique (Institut Universitaire du Cancer Toulouse Oncopole)   26 février 2024
Improved nationwide survival of sarcoma patients with a network of reference centers.
Annals of oncology : official journal of the European Society for Medical Oncology   19 janvier 2024
Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years.
European journal of cancer (Oxford, England : 1990)   23 novembre 2023
REGOBONE: A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Essai Clinique (Unicancer)   06 novembre 2023
RIBOLARIS: Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer
Essai Clinique (Novartis)   06 octobre 2023
1913O A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1928P Differential presentation and outcome of sclerosing epithelioid fibrosarcoma (SEF) vs low grade fibromyxoid sarcoma (LGFMS): The nationwide series of 330 patients in NETSARC since 2010
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
MIRAS: Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
Essai Clinique (Institut Universitaire du Cancer Toulouse Oncopole)   22 septembre 2023
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten): Randomized, Multicentre, Phase II Study Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After at Least 10 Years of Treatment in Patients With Locally Advanced/Metastatic Gastrointestinal Stromal Tumors (GISTs)
Essai Clinique (Centre Léon-Bérard)   31 août 2023
REGOSTA: A Randomized, Placebo-controlled, Double-blinded, Multicentre Study Evaluating the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Essai Clinique (Centre Léon-Bérard)   07 août 2023